Skip to Main Content

Paper Details

Combination therapy as a potential risk factor for the development of type 2 diabetes in patients with schizophrenia: the GOMAP study.
BMC Psychiatry
3
2018
Metabolic and Psychiatric disease, Patients, SCZ, Schizophrenia, T2D, patients, schizophrenia, type 2 diabetes
Author NameAffiliation
Vasiliki MamakouNational and Kapodistrian University Athens
Vasiliki MamakouDromokaiteio Psychiatric Hospital
Sophie HackingerWellcome Sanger Institute
Eirini MarouliWilliam Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London
Bram P PrinsWellcome Sanger Institute
Lorraine SouthamWellcome Sanger Institute
Lorraine SouthamUniversity of Oxford
Nigel W RaynerWellcome Sanger Institute
Nigel W RaynerUniversity of Oxford
Nigel W Rayner
George DedoussisHarokopio University
Eleftheria ZegginiWellcome Sanger Institute
  • 1 - 12

Datasets

Release 1.2